Clinical Trials
12 trialsNCT03812549 2025-03-04
Safety and Tolerability Evaluation of Sintilimab in Combination With Radiation in Stage IV NSCLC Patients
Sichuan University
Phase 1 Completed
NCT05119998 2023-08-18
A Phase I Study of IBI325 in Patients With Advanced Solid Tumor
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Completed
NCT05026593 2023-07-19
A Study of IBI110 in Combination With Sintilimab and Chemotherapy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Completed
NCT04672356 2023-06-22
A Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung Cancer
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Completed
NCT04672369 2023-06-22
A Study to Evaluate the Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced NSCLC
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Completed
NCT03732664 2023-03-24
ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1 Completed
NCT03545971 2023-02-28
A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors.
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Completed
NCT04177290 2023-02-27
A PK Similarity Study of Two Sintilimab Products Produced by Different Processes in Advanced or Metastatic NSCLC Patients
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Completed
NCT05118334 2023-02-23
IBI310 (Anti-CTLA-4) in Combination With Sintilimab in Patients With Non-small-cell Lung Cancer (NSCLC)
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Completed
NCT03758001 2023-02-22
First in Human Study of IBI101 in Chinese Subjects With Advanced Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Completed
NCT02937116 2022-10-14
First in Human Study of IBI308 in Chinese Subjects With Advanced Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Completed
NCT03568539 2021-06-01
IBI308 in Subjects With Advanced/Metastatic Solid Malignancies
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Completed